Rakovina Therapeutics Inc.
RKV.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -55.36% | 2.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -41.64% | 38.89% | |||
| Operating Income | 41.64% | -38.89% | |||
| Income Before Tax | 38.64% | -38.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 38.64% | -38.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.64% | -38.80% | |||
| EBIT | 41.64% | -38.89% | |||
| EBITDA | 43.79% | -41.16% | |||
| EPS Basic | 53.81% | -22.80% | |||
| Normalized Basic EPS | 53.86% | -22.85% | |||
| EPS Diluted | 53.81% | 4.95% | |||
| Normalized Diluted EPS | 53.86% | -22.85% | |||
| Average Basic Shares Outstanding | 32.93% | 13.02% | |||
| Average Diluted Shares Outstanding | 32.93% | 13.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||